Komori
Earnings presentation4118KANEKA CORPORATIONMaterials and Chemicals

Earnings Presentation Materials for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027

For the interim period of the fiscal year ending March 2027, all segments posted higher revenue and profit, with net sales and operating profit reaching record highs for an interim period. The full-year earnings forecasts were raised, and the full-year dividend forecast was increased from ¥210 to ¥215.

Worth reading
78Important
Scored from 4 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
137
¥100 million (year-on-year increase in operating income)
Wording
Conditional
How definitive the wording is.

Contents of this document

Earnings presentationSecond quarter (interim period) of the fiscal year ending March 20278 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥4,470 100 million+12.5%
Operating profit¥287 100 million+91.7%
Ordinary income¥243 100 million+106.8%
Net income¥146 100 million +32.5%interim net income attributable to owners of the parent
Operating profit margin6.4 %
Results for the three months of the current quarter
Net Sales
¥2,239 100 million
comparison+0.4% vs. 1Q
Operating profit
¥137 100 million
comparison△8.1% vs. 1Q
By segmentMaterial SU: net sales ¥90.5 billion, operating profit ¥8.4 billion; Quality of Life SU: net sales ¥54.3 billion, operating profit ¥7.9 billion; Health Care SU: net sales ¥23.5 billion, operating profit ¥3.6 billion; Nutrition SU: net sales ¥55.4 billion, operating profit ¥3.9 billion
Full-year earnings forecast
Net Sales
¥8,900 100 million
Operating profit
¥480 100 million
Ordinary income
¥415 100 million
Profit attributable to owners of the parent
¥320 100 million
Operating profit margin
5.4 %
Earnings per share
¥536.33
Dividend per share
¥215
What the company explained in this material
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
  • Average exchange rate during the period (US dollar)
    Forecast for the fiscal year ending March 2027155
  • Average exchange rate during the period (euro)
    Forecast for the fiscal year ending March 2027178
  • Domestic naphtha
    Forecast for the fiscal year ending March 2027120,000
New initiatives
  • Launch of the new product “Susumu Chikara Lemon Myrtle Drink: Refreshing Citrus Flavor”
  • Advancing the development of mass-production technology for tandem perovskite solar cells
  • Expanding sales of new Medical products and sales regions (the United States and China)
Key KPIsA metric the company considers important as a management benchmark.
  • First-half net income per share¥243.48
    Year on year against the same period last year+37.9%
  • Equity ratio51.4 %
  • D/E ratio0.44 Times
  • Cash flows from operating activities¥297 100 million
  • Free cash flow¥17 100 million
  • Balance of cash and cash equivalents at period-end¥551 100 million
Segment results
Material SU
Net Sales
¥1,850 100 million+13.8%
Operating profit
¥193 100 million+53.1%
Quality of Life SU
Net Sales
¥1,082 100 million+11.5%
Operating profit
¥149 100 million+57.7%
Health Care SU
Net Sales
¥455 100 million+21.8%
Operating profit
¥68 100 million+19.5%
Nutrition SU
Net Sales
¥1,079 100 million+7.8%
Operating profit
¥73 100 million+21.8%
Other
Net Sales
¥5 100 million+2.3%
Operating profit
¥2 100 million+1.4%
Financial targets
ROE
Forecast for the fiscal year ending March 20276.4 %
Equity ratio
Actual results51.4 %
Debt-to-equity ratio
Actual results0.44 Times
Annual Dividend
Annual dividend per share¥215
Payout ratio
40.1 %
Shareholder Return PolicyConsolidated payout ratio of 40% or higher as a guideline
Acquisition of treasury shares
70
Amount unit¥100 million
Number of Shares140
Share unit10,000 shares (maximum)
PeriodMay 2026–March 2027
Contents of this document
ItemDetails
Document typeEarnings presentation
Fiscal Period CoveredSecond quarter (interim period) of the fiscal year ending March 2027
Net Sales¥4,470 100 million (YoY +12.5%)
Operating profit¥287 100 million (YoY +91.7%)
Ordinary income¥243 100 million (YoY +106.8%)
Net income¥146 100 million (interim net income attributable to owners of the parent) (YoY +32.5%)
Operating profit margin6.4 %
Results for the three months of the current quarterNet Sales ¥2,239 100 million / Operating profit ¥137 100 million / By segment Material SU: net sales ¥90.5 billion, operating profit ¥8.4 billion; Quality of Life SU: net sales ¥54.3 billion, operating profit ¥7.9 billion; Health Care SU: net sales ¥23.5 billion, operating profit ¥3.6 billion; Nutrition SU: net sales ¥55.4 billion, operating profit ¥3.9 billion
Full-year earnings forecastNet Sales ¥8,900 100 million / Operating profit ¥480 100 million / Ordinary income ¥415 100 million / Profit attributable to owners of the parent ¥320 100 million / Operating profit margin 5.4 % / Earnings per share ¥536.33 / Dividend per share ¥215
Segment resultsMaterial SU Net Sales ¥1,850 100 million (YoY +13.8%) / Operating profit ¥193 100 million (YoY +53.1%) / Quality of Life SU Net Sales ¥1,082 100 million (YoY +11.5%) / Operating profit ¥149 100 million (YoY +57.7%) / Health Care SU Net Sales ¥455 100 million (YoY +21.8%) / Operating profit ¥68 100 million (YoY +19.5%) / Nutrition SU Net Sales ¥1,079 100 million (YoY +7.8%) / Operating profit ¥73 100 million (YoY +21.8%) / Other Net Sales ¥5 100 million (YoY +2.3%) / Operating profit ¥2 100 million (YoY +1.4%)
Key KPIsIndicator name First-half net income per share / Value ¥243.48 / Year on year against the same period last year ¥37.9, Indicator name Equity ratio / Value 51.4 % / Year on year against the same period last year Not disclosed, Indicator name D/E ratio / Value 0.44 Times / Year on year against the same period last year Not disclosed, Indicator name Cash flows from operating activities / Value ¥297 100 million / Year on year against the same period last year Not disclosed, Indicator name Free cash flow / Value ¥17 100 million / Year on year against the same period last year Not disclosed, Indicator name Balance of cash and cash equivalents at period-end / Value ¥551 100 million / Year on year against the same period last year Not disclosed
Assumptions Underlying the Business OutlookItem Average exchange rate during the period (US dollar) / Forecast for the fiscal year ending March 2027 ¥155, Item Average exchange rate during the period (euro) / Forecast for the fiscal year ending March 2027 ¥178, Item Domestic naphtha / Forecast for the fiscal year ending March 2027 ¥120,000
Financial targetsROE Forecast for the fiscal year ending March 2027 6.4 % / Equity ratio Actual results 51.4 % / Debt-to-equity ratio Actual results 0.44 Times
Annual DividendAnnual dividend per share ¥215 / Interim and Year-End Breakdown Not disclosed
Payout ratio40.1 %
Acquisition of treasury sharesAmount 70 / Amount unit ¥100 million / Number of Shares 140 / Share unit 10,000 shares (maximum) / Period May 2026–March 2027
New initiativesLaunch of the new product “Susumu Chikara Lemon Myrtle Drink: Refreshing Citrus Flavor”, Advancing the development of mass-production technology for tandem perovskite solar cells, Expanding sales of new Medical products and sales regions (the United States and China)
Items this document does not state (14)
Gross Profit MarginSelling, general and administrative expensesProgress against full-year forecastSelf-assessment against the planBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company cited stable supply and price revisions, its response to strong demand, expanded sales of high-value-added products, overseas expansion and M&A in Medical, and increased sales of reduced CoQ10 products as factors behind the increases in revenue and profit.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Earnings Presentation Materials for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 | KANEKA CORPORATION (4118) timely disclosure | Komori